Evidence map›Paper›PMID 39422741›Full record

Trial reportCancer chemotherapy and pharmacology2024

An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors.

Zeynep Eroglu, Timothy Synold, Behnam Badie, An Liu, Arnab Chowdhury, Julie Kilpatrick, Suzette Blanchard, Jana Portnow

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer chemotherapy and pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02338037 (An Intracerebral Microdialysis Study to Determine the Neuropharmacokinetics of Eribulin in Patients With Brain Tumors), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02338037 early_phase1completednot on this map

An Intracerebral Microdialysis Study to Determine the Neuropharmacokinetics of Eribulin in Patients With Brain Tumors

TypeinterventionalSponsorCity of Hope Medical CenterRan2015 to 2024Enrolled8ConditionsMetastatic Malignant Neoplasm in the Adult Brain, Primary Brain TumorArmsTherapeutic Conventional Surgery, Biopsy, Eribulin Mesylate, Microdialysis, Pharmacological Study
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zeynep ErogluCity of Hope Comprehensive Cancer Center, Department of Medical Oncology and Therapeutics Research, Duarte, CA, USA.
Timothy SynoldDepartment of Cancer Biology, Beckman Research Institute of City of Hope, Duarte, CA, USA.
Behnam BadieDepartment of Surgery, Division of Neurosurgery, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
An LiuDepartment of Radiation Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Arnab ChowdhuryDepartment of Computational and Quantitative Medicine, Beckman Research Institute of City of Hope, Duarte, CA, USA.
Julie KilpatrickDepartmant of Clinical Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Suzette BlanchardDepartment of Computational and Quantitative Medicine, Beckman Research Institute of City of Hope, Duarte, CA, USA.
Jana PortnowCity of Hope Comprehensive Cancer Center, Department of Medical Oncology and Therapeutics Research, Duarte, CA, USA. jportnow@coh.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEribulin is an inhibitor of microtubule dynamics. It is not as highly protein bound as the taxanes and is less vulnerable to extrusion by P-glycoprotein in the blood-brain barrier (BBB). These features predict that eribulin could play an active role in managing brain tumors. Indeed, the small amount of published clinical data indicates eribulin may have some efficacy against breast cancer brain metastases. To better understand the potential of eribulin for treating brain tumors, we performed an intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in cancer patients undergoing tumor resection.

methodsAfter tumor removal, two microdialysis catheters were inserted into peritumoral brain tissue. Approximately 24 h after surgery, a single dose of eribulin 1.4 mg/m

resultsDialysate samples from 12 intracerebral microdialysis catheters placed in 7 study participants were included in the analysis. A statistically significant difference was observed between eribulin concentrations in brain tissue where BBB was disrupted versus intact, with a difference in mean maximum concentrations on log

conclusionAlthough we could detect higher concentrations of eribulin in brain tissue where BBB was disrupted, intracerebral eribulin levels were not sufficient to predict eribulin would have consistent clinically meaningful activity against tumors in the brain. CLINICALTRIALS: GOV IDENTIFIER: NCT02338037 (January 9, 2015).

Indexed as

Brain NeoplasmsFuransKetonesMicrodialysisAdultAgedAntineoplastic AgentsBlood-Brain BarrierBrainFemaleHumansMaleMiddle AgedPolyether PolyketidesTandem Mass SpectrometryAntineoplastic AgentseribulinFuransKetonesPolyether PolyketidesBrain metastasesEribulinGlioblastomaIntracerebral microdialysis

Identifiers

PMID39422741
PMCPMC11573798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.